Soleno Therapeutics (NASDAQ: SLNO)
Soleno Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Soleno Therapeutics Company Info
Soleno Therapeutics, Inc. operates as clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of rare diseases. It focuses on the treatment of metabolic and neurobehavioral disorder. It offers its lead candidate, Diazoxide Choline Controlled-Release (DCCR), an oral tablet for the treatment of Prader-Willi Syndrome (PWS). The company was founded on August 25, 1999 and is headquartered in Redwood City, CA.
News & Analysis
Why Soleno Therapeutics Stock Blasted 9% Higher Today
The company's Prader-Willi treatment inched closer to FDA approval.
Why Soleno Therapeutics Stock Is Skyrocketing Today
The clinical-stage biotech company received great news from the FDA.
Why Soleno Therapeutics Stock Ticked Higher on Thursday
The latest pundit take on the stock provided a good reason for bulls to snap it up.
Why Shares of Soleno Therapeutics Dropped on Wednesday
Investors took profits a day after the clinical-stage biotech company's shares soared.
Why Shares of Soleno Therapeutics Are Booming on Tuesday
Soleno announced positive top-line results for DCCR, its lead therapy.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.